LEO SAFETY AND EFFICACY OF ESCALATING DOSES OF TWO LEO 43204 FORMULATIONS APPLIED ONCE DAILY FOR TWO CONSECUTIVE DAYS ON FULL FACE OR APPROXIMATELY 250 CM2 (40 IN2) ON THE CHEST IN SUBJECTS WITH ACTINIC KERATOSIS; PART 2: A PHASE 2, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, VEHICLE-CONTROLLED, 8-WEEK TRIAL OF LEO 43204 GEL IN SUBJECTS WITH AK (CANADA AND US)

Registry ID

LP0084-1013

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

LEO PHARMA AS

Start date

2014-05-28

Last update

2014-05-22

Conditions

• ACTINIC KERATOSIS

Related clinical trials

• EFFICACY AND SAFETY OF INGENOL MEBUTATE GEL IN FIELD TREATMENT OF ACTINIC KERATOSIS ON FULL FACE, BALDING SCALP OR APPROXIMATELY 250 CM2 ON THE CHEST
• SAFETY AND EFFICACY OF ESCALATING DOSES OF LEO 43204 APPLIED ONCE DAILY FOR TWO CONSECUTIVE DAYS ON APPROXIMATELY 250 CM2 ON TRUNK AND EXTREMITIES IN SUBJECTS WITH ACTINIC KERATOSIS. PART 2 (CANADA): A PHASE 2, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, VEHICLE-CONTROLLED, 8-WEEK TRIAL

View on source registry